Health Technology

Lightbeam Health Solutions Announces Acquisition of CareSignal, the pioneer of Deviceless Remote Patient Monitoring technology

Lightbeam Health Solutions, Inc., the leader in end-to-end population health management solutions, announced today the acquisition of CareSignal, the pioneer of Deviceless Remote Patient Monitoring technology. The deal enables Lightbeam to integrate scalable, evidence-based remote engagement and monitoring capabilities into its core population health offering, which serves more than 42 million patient lives across the United States.

Together, Lightbeam and CareSignal will deliver best-in-class population-level stratification, actionable real-time insight delivery, and clinical outcome improvement. Current and future industry partners of both companies will benefit from the validated offerings and deep focus on client success.

CareSignal brings over 30 condition-specific programs, proven real-world ROI, and a suite of robust AI-based predictive models that complement Lightbeam’s sophisticated population health analytics platform. Combined with the real-time cohort generation capabilities at the core of Lightbeam, CareSignal programs covering chronic conditions, behavioral health, social determinants of health, maternal health, and additional use cases will rapidly generate scalable returns on investment for value-based providers, payers, and self-insured employers.

“Lightbeam and CareSignal share a vision for the future of healthcare: care that is proactive, cost-effective, and data-driven. Lightbeam continues to see double-digit year-over-year growth, and CareSignal will help further accelerate our mission to deliver a revolutionary approach to population and risk management.”

Lightbeam Founder and CEO, Pat Cline

“As part of Lightbeam, I have deep conviction that the CareSignal product and team will achieve the greatest possible impact, delivering clinical and financial value for the patients and healthcare organizations that have the most to gain,” said Blake Marggraff, CareSignal Co-Founder and CEO. “Speaking on behalf of the CareSignal founding team, we are inspired by Lightbeam’s focus on operational excellence, sustainable differentiation, and value creation, along with their deep industry expertise. We are excited to bring our combined businesses to the next level.”

About Lightbeam Health Solutions
Lightbeam Health Solutions delivers a proven model for managing patient populations and associated risk. Lightbeam’s vision is to bring health data into the light through the use of analytics, and to provide the insight and capabilities healthcare clients need to ensure patients receive the right care at the right time. Lightbeam’s platform facilitates end-to-end population health management for ACOs, payers, provider groups, health systems, and other healthcare organizations aspiring to provide superior care at a lower cost. 

About CareSignal
CareSignal offers Deviceless Remote Patient Monitoring: SMS (text message) and phone-based engagement programs specifically designed for value-based care. The company leverages real-time, self-reported patient data and artificial intelligence to produce long-term patient engagement while identifying clinically actionable moments for proactive care delivery. Proven in 13 peer-reviewed studies and dozens of payer and provider implementations to sustainably scale care teams to manage over ten times more patients, CareSignal drives significant improvements in chronic and behavioral health outcomes, quality measures, and reduced global utilization. 

Spotlight

Other News
Health Technology, AI

Swoop Launches AI-Powered Conversational Agent for Healthcare Marketing, Revolutionizing Engagement on brand.com

Swoop | January 09, 2024

Swoop, a leader in developing precise direct to consumer (DTC) and healthcare provider (HCP) audiences for pharmaceutical and life sciences brands, today announced the launch of its AI-powered conversational agent. This groundbreaking advancement in healthcare marketing sets a new standard for lower funnel engagement, enabling immediate, MLR-compliant virtual customer interactions via brand.com. “Swoop’s AI-powered conversational agent marks the first groundbreaking advancement for brand.com since the introduction of pharmaceutical websites in the 1990s, addressing a pressing need for innovation in how the industry engages with their customers,” said Scott Rines, underscoring the historic significance of this achievement. “Patients and physicians are looking for real-time information, 24/7/365 during their moment of need, but are often faced with an overwhelming experience on brand.com. They come to the site seeking fast, clear answers to their health-related questions – our agent solves this.” Market conditions continue to remain a challenge with shortages of healthcare professionals despite an uptick in customer demand for information related to their condition and treatment decisions. Meanwhile, HCPs are also less likely to allow medical reps into their offices, a shift that has continued post-Covid. Instead, these increasingly digital-native, often over-extended, physicians prefer to seek information online when their schedule permits, limiting the impact of personal promotion. “The ability to parse the data derived from lower funnel conversations with HCPs and patients in real time will prove invaluable, as these signals will become proprietary 1st party data to optimize future marketing spend and messaging,” added Rines. Key Features of Swoop's Conversational Agent Dynamic Patient Conversations: Patients and HCPs can engage with conversational AI in real-time, creating a personalized and responsive user experience to drive more high-value actions on a health brand website. MLR-Approved Medical Information: Leveraging advanced algorithms, conversational AI provides MLR-approved answers to both simple and complex medical questions in the moment of need, enhancing the overall user experience for both patients and HCPs. Real-Time Patient Insights: Valuable real-time data from conversations accessible via dashboards allows healthcare brands to assess the effectiveness of their messaging and make informed adjustments promptly. Scalable to Client Demands: Whether for a single brand, therapeutic area or product portfolio, Swoop conversational AI agents can scale with the needs of healthcare marketers from new product launches to covering open territories and unsupported brands. Patient Data Security and Compliance: Swoop prioritizes patient privacy and data security, ensuring that all conversational AI agents operate in compliance with the highest industry standards and regulations. Typical Client Results Seen by Customers 96% – Average answer success rate of inquiries 5.2 minutes – Typical conversation duration 4.7/5 – Average user satisfaction rating 800% – Increase in high-value activities on brand websites Swoop’s conversational AI technology is built on more than 1.3 billion conversations with patients and providers and has been trained under the supervision of physicians and medically trained clinicians. Unlike generative AI, which can hallucinate and is not appropriate for direct patient and HCP interaction in the heavily regulated pharmaceutical industry, Swoop conversational AI uses fine-tuned large language models to understand user intent and surface the most relevant MLR-approved answers to ensure compliance, accuracy and, most importantly, safety. About Swoop Swoop, part of Real Chemistry, enables pharmaceutical and life sciences brands to reach their ideal DTC and HCP audiences at crucial moments of their diagnosis and treatment journey. Using ML/AI and real world data, Swoop is a leader in developing brand-exclusive audiences of patients and their providers for healthcare companies. Once the right customers have been targeted, brands can drive bottom-of-the-funnel engagement through Swoop’s proprietary medically trained and MLR-compliant conversational AI. Built on a privacy-by-design foundation, Swoop is both HIPAA-certified and NAI accredited, having developed more than 12,000 unique target audiences for 42 of the top 50 pharmaceutical companies safely. Its conversational AI has been implemented across 100 health brands and trained on over 1.3 billion medical conversations.

Read More

Health Technology

BroadcastMed Launches New Platform for Vision Portfolio of Products

BroadcastMed | January 25, 2024

BroadcastMed, the leading healthcare information marketplace that provides trusted clinical content, powerful engagement, and industry insights to healthcare professionals (HCPs), medical institutions and manufacturers, service providers, and pharmaceutical companies, is thrilled to announce the evolution of its Vision portfolio. PentaVision, powered by BroadcastMed, released a new digital platform designed to elevate the user experience for healthcare and optical professionals. Driven by many of the industry's leading Optometry and Ophthalmology publications, the platform leverages an intricate network that spans across their entire suite of Vision brands. The architecture was designed to provide HCPs with vibrant, interactive content within personalized user experiences. Real-time industry data has been optimized, ensuring that HCPs remain informed of the latest developments, trends, and breakthroughs in the field. With a user-centric design, the platform enables HCPs to navigate effortlessly, thereby saving time and enhancing efficiency in accessing the most pertinent and valuable content. This dedication to convenience fosters continuous learning, collaboration, and professional growth. "We are delighted about the positive impact this enhanced network will have on our partners' ability to connect with HCPs in a meaningful way," said Lee Schweizer, Chief Digital Officer, BroadcastMed. "With optimized architecture for improved search visibility, a network-buying approach for advertisers, and plans for dynamic content in 2024, we're excited to offer enhanced benefits for both advertisers and healthcare providers." "The new Retinal Physician website offers faster navigation, improved content, and a streamlined interface. I think the changes will be appreciated by everyone!" said Peter K. Kaiser, MD, Professor of Ophthalmology, Chaney Family Endowed Chair in Ophthalmology Research. BroadcastMed, together with 424 Capital, a growth capital partner, acquired PentaVision in August of 2022 to expand its healthcare audience and secure high-quality content across 11 brands in vision care. PentaVision's media brands are among the most respected and read brands globally, and include Contact Lens Spectrum, Corneal Physician, Eyecare Business, Glaucoma Physician, New Retinal Physician, Optometric Management, Ophthalmology Management, Ophthalmic Professional, Presbyopia Physician, and Retinal Physician. Underlining its commitment to evolving content distribution, expanding multichannel reach, fostering engaging live events and streaming experiences, and providing insightful data to HCPs and supporting organizations, BroadcastMed is dedicated to advancing the field of healthcare. About BroadcastMed BroadcastMed is the leading healthcare information marketplace that provides trusted clinical content, powerful engagement and industry insights to healthcare professionals, medical institutions and manufacturers, service providers and pharmaceutical companies. The company's integrated platform of digital, event, and publication solutions helps drive better dialogue, connectivity, and outcomes for the healthcare community.

Read More

Healthcare Analytics

Aya Healthcare Expands into UK with ID Medical Acquisition

Aya Healthcare | January 17, 2024

Aya Healthcare, the largest healthcare talent software and staffing company in the United States, today announced the acquisition of ID Medical, a leading workforce solutions provider in the United Kingdom (U.K.). ID Medical brings over 20 years of experience providing the National Health Service (NHS) and other healthcare organizations with innovative workforce solutions, including workforce management, international recruitment and temporary healthcare staffing. As part of the acquisition, ID Medical will make Aya Healthcare’s market-leading technology available to the NHS and U.K.-based clinicians. The companies plan to share best practices from each market with their respective clients. “We are excited about ID Medical joining the Aya family of brands. We believe that we will deliver enhanced value to our respective clients and clinicians through this cross-Atlantic collaboration,” said Alan Braynin, president and CEO of Aya Healthcare. ID Medical will continue to operate as its own brand in the U.K., supporting thousands of healthcare professionals and hundreds of healthcare organizations. “We are excited to join Aya in our shared mission to transform the healthcare industry worldwide,” said Deenu Patel, CEO of ID Medical. “With Aya’s support, we’ll have access to additional resources, technology and expertise to enhance our services and expand our impact.” About Aya Healthcare Aya Healthcare is the largest healthcare talent software and staffing company in the United States. Aya operates the world’s largest digital staffing platform delivering every component of healthcare-focused labor services, including travel nursing and allied health, per diem, permanent staff hiring, interim leadership, locum tenens and non-clinical professionals. Aya’s software suite, which includes vendor management, float pool technology, provider services and predictive analytics, provides hospital systems greater efficiencies, superior operating results and reduced labor costs. While technology drives efficiency and scale, Aya’s 7,000+ global employees power the company to deliver unparalleled accountability and exceptional experiences for clients and clinicians. Aya’s company culture is rooted in giving back and supports organizations around food security, education, healthcare, safe shelter and equity.

Read More

Healthcare Analytics

SHL Medical partners with SteriPack Group to set up final assembly service

SHL Medical | January 24, 2024

SHL Medical, a world-leading solutions provider of advanced drug delivery systems and SteriPack Group, renowned global supplier of secondary packing and final assembly services to the pharmaceutical industry, enter a non-exclusive strategic partnership. Together, they aim to establish a pre-validated final assembly service at the SteriPack facility in Poland, enhancing the overall flexibility of supply chain strategies for their customers. In addition to SHL Medical's existing final assembly, labeling, and packaging­ services in the United States, this collaboration extends high-quality CMO options to Europe. Markus Puusepp, SHL Medical's Chief Growth Officer, expressed enthusiasm about the partnership, stating "This partnership is a significant addition to the Molly® platform value proposition. We share common values with SteriPack, from focus on the customer to a commitment to quality, making the decision to collaborate straightforward." Recognizing the importance of flexibility and time-to-market, especially in clinical production, the partnership with SteriPack will offer SHL Medical's customers highly flexible and personalized final assembly and packaging solutions. This is particularly beneficial for small batch handling in clinical supply and niche markets like rare diseases. Emphasizing the comprehensive capabilities of the Molly platform, SHL Medical aims to deliver right-sized solutions that ensure improved service, faster timelines, and a more streamlined supply chain for its diverse customer base. John Ward, SteriPack Group's VP Pharmaceutical Solutions commented "SteriPack Group looks forward to supporting SHL Medical and their customers in providing quality and flexible solutions to a fast- moving market. With an emphasis on creating service solutions designed around specific customer requirements, this partnership will make the process of working with the Molly® platform an easy decision." About SHL Medical As a world-leading solutions provider of advanced drug delivery systems, SHL Medical is the partner of choice for many leading pharma and biotech companies. Driven by its company purpose – Enabling Patients' Independence – SHL Medical offers patient-centric solutions for the design, development, and manufacturing of autoinjectors, pen injectors, as well as innovative specialty delivery systems for large-volume and high-viscosity formulations. It also offers final assembly, labeling, and packaging solutions for its drug delivery systems. In response to the rising trend in home therapy, SHL Medical has increased its developmental work in the digital healthcare sector to help improve the drug delivery ecosystem. Located across Switzerland, Taiwan, Sweden, and the US, SHL Medical's global team of experts collaborate seamlessly as one team in utilizing its comprehensive in-house manufacturing capabilities. Its solutions offer customization and optimization for each project while proactively weaving sustainability-driven measures into its designs and processes to contribute to a cleaner earth. About SteriPack Group SteriPack Group is a globally renowned contract packing and manufacturing organisation serving the pharmaceutical and medical device sectors respectively. With a strong emphasis on innovation, quality and compliance, SteriPack's services to the pharmaceutical industry include device design and development, final assembly, labelling, secondary packing, serialisation and aggregation of injectable formats including vials, pre-filled syringes, and autoinjectors. SteriPack's tailored customer-focused solutions make it an ideally suited supplier for small to medium-sized batch volumes required for a growing market of targeted therapies as well as clinical trials. Its proven capabilities in cleanroom assembly and labelling as well as secondary packing services for drug delivery systems and medical devices, combined with significant investment into growing cold chain storage capacity, have helped to make it a trusted partner to top global pharmaceutical companies.

Read More